NHS England Launches STRIDE-RCT Trial for Multi-Cancer Blood Screening

Key points

• The STRIDE-RCT trial will screen for 13 cancers, including bowel, pancreatic, liver, ovarian, and prostate.
• Approximately 71,000 people in England are diagnosed annually with these specific cancers, with nearly 35,000 deaths.
• Patients provide one or two blood tubes at GP surgeries, analyzed for tumor DNA signals.
• Positive results do not confirm cancer, and negative results do not guarantee its absence.
• Health Secretary Yvette Cooper hopes the test will accelerate urgent investigations for at-risk patients.

Background

This development follows recent debates over the Grail Galleri test, which screens for over 50 cancer types. Previous NHS-Galleri trials involving 142,250 participants found that while the test detected about 30% of cancers, it did not significantly reduce late-stage diagnoses overall. FDA approval for similar multi-cancer tests has also faced scrutiny regarding clinical efficacy and false negatives.

How outlets are covering it

BBC emphasizes the practical rollout in GP surgeries and the difficulty of detecting abdominal cancers due to vague symptoms. The Conversation highlights the scientific potential of liquid biopsy to detect weak genetic signals before symptoms appear, while noting technical challenges in distinguishing true mutations from sequencing errors. Hospital News provided no substantive content, only a cookie consent notice. The BBC notes that a positive result requires further investigation, whereas The Conversation focuses on the precision of detecting circulating tumor DNA.

Why it matters

Early detection is critical for survival rates in cancers that lack standard screening methods. If successful, this trial could reduce the burden of late-stage diagnoses in England, potentially saving lives and reducing treatment costs. However, the mixed results of previous trials suggest that widespread adoption may not yield the expected mortality reductions without further validation.

What to watch

The STRIDE-RCT trial will analyze blood samples for signs of cancer and attempt to locate the tumor. Results will determine if the test can reliably identify patients needing urgent investigation. Broader adoption depends on proving clinical efficacy and managing false positives/negatives.